

DEPARTMENT OF JUSTICE**Drug Enforcement Administration**
[Docket No. DEA-392]**Bulk Manufacturer of Controlled Substances Application: Chemtos, LLC****ACTION:** Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 27, 2014.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR pt. 0, subpt. R, App.

In accordance with 21 CFR 1301.33(a), this is notice that on June 6, 2014, Chemtos, LLC, 14101 W. Highway 290, Building 2000B, Austin, Texas 78737-9331, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
Amphetamine (1100)	II
Methamphetamine (1105)	II
Lisdexamfetamine (1205)	II
Methylphenidate (1724)	II
Nabilone (7379)	II
Phenylacetone (8501)	II
Cocaine (9041)	II
Codeine (9050)	II
Etorphine HCl (9059)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II

Controlled substance	Schedule
Ecgognine (9180)	II
Ethylmorphine (9190)	II
Hydrocodone (9193)	II
Levomethorphan (9210)	II
Levorphanol (9220)	II
Isomethadone (9226)	II
Meperidine (9230)	II
Meperidine intermediate-A (9232)	II
Meperidine intermediate-B (9233)	II
Meperidine intermediate-C (9234)	II
Methadone (9250)	II
Methadone intermediate (9254)	II
Morphine (9300)	II
Thebaine (9333)	II
Dihydroetorphine (9334)	II
Levo-alphacetylmethadol (9648)	II
Oxymorphone (9652)	II
Racemethorphan (9732)	II
Racemorphan (9733)	II

The company plans to manufacture small quantities of the listed controlled substances in bulk for distribution to its customers for use as reference standards.

Dated: August 19, 2014.

Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-20195 Filed 8-25-14; 8:45 am]
BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE**Drug Enforcement Administration****[Docket No. DEA-392]****Bulk Manufacturer of Controlled Substances Application: Cerilliant Corporation****ACTION:** Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before October 27, 2014.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. Request for hearings should be sent to: Drug Enforcement

Administration, Attention: Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and

implementation of 21 CFR part 1301, incident to the registration of manufacturers, of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR pt. 0, subpt. R, App.

In accordance with 21 CFR 1301.33(a), this is notice that on June 9, 2014, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665-2402, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
3-Fluoro-N-methylcathinone (3-FMC) (1233).	I
Cathinone (1235)	I
Methcathinone (1237)	I
4-Fluoro-N-methylcathinone (4-FMC) (1238).	I
Pentedrone (α-methylaminovalerophenone) (1246).	I
Mephedrone (4-Methyl-N-methylcathinone) (1248).	I
4-Methyl-N-ethylcathinone (4-MEC) (1249).	I
Naphyrone (1258)	I
N-Ethylamphetamine (1475)	I
N,N-Dimethylamphetamine (1480)	I
Fenethylline (1503)	I
Aminorex (1585)	I
4-Methylaminorex (cis isomer) (1590).	I
Gamma Hydroxybutyric Acid (2010).	I
Methaqualone (2565)	I
JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) (6250).	I
SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) (7008).	I
5-Fluoro-UR-144 and XLR11 [1-(5-Fluoro-pentyl) 1-H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl) methanone (7011).	I
AB-FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) (7012).	I
JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) (7019).	I
ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) (7035).	I
APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide (7048).	I
JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) (7081).	I

Controlled substance	Schedule	Controlled substance	Schedule	Controlled substance	Schedule
SR-19 and RCS-4 (1-Pentyl-3[4-methoxy-benzoyl]indole (7104).	I	3,4-Methylenedioxymethamphetamine (7405).	I	Hydromorphone (9301)	I
JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) (7118).	I	4-Methoxyamphetamine (7411) ...	I	Methyldesorphine (9302)	I
JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) (7122).	I	5-Methoxy-N-N-dimethyltryptamine (7431).	I	Methyldihydromorphone (9304)	I
UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (7144).	I	Alpha-methyltryptamine (7432)	I	Morphine methylbromide (9305) ..	I
JWH-073 (1-Butyl-3-(1-naphthoyl)indole) (7173).	I	Bufotenine (7433)	I	Morphine methylsulfonate (9306)	I
JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) (7200).	I	Diethyltryptamine (7434)	I	Morphine-N-oxide (9307)	I
AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) (7201).	I	Dimethyltryptamine (7435)	I	Normorphine (9313)	I
JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) (7203).	I	Psilocybin (7437)	I	Pholcodine (9314)	I
PB-22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) (7222).	I	Psilocyn (7438)	I	Acetylmethadol (9601)	I
5F-PB-22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) (7225).	I	5-Methoxy-N,N-diisopropyltryptamine (7439).	I	Allylprodine (9602)	I
Alpha-ethyltryptamine (7249)	I	N-Ethyl-1-phenylcyclohexylamine (7455).	I	Alphacetylmethadol except levo-alphacetylmethadol (9603).	I
CP-47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) (7297).	I	1-(1-Phenylcyclohexyl)pyrrolidine (7458).	I	Alphameprodine (9604)	I
CP-47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) (7298).	I	1-[1-(2-Thienyl)cyclohexyl]piperidine (7470).	I	Alphamethadol (9605)	I
Lysergic acid diethylamide (7315)	I	N-Benzylpiperazine (7493)	I	Betacetylmethadol (9607)	I
2,5-Dimethoxy-4-(n-propylthiophenethylamine (2C-T-7) (7348).	I	4-Methyl-alpha-pyrrolidinopropiophenone (4-mePPP) (7498).	I	Betameprodine (9608)	I
Marijuana (7360)	I	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) (7508).	I	Betamethadol (9609)	I
Tetrahydrocannabinols (7370)	I	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) (7509).	I	Betaprodine (9611)	I
Parahexyl (7374)	I	2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) (7517).	I	Dipipanone (9622)	I
Mescaline (7381)	I	2-(4-ido-2,5-dimethoxyphenyl)ethanamine (2C-I) (7518).	I	Hydroxypethidine (9627)	I
2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2) (7385).	I	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) (7519).	I	Noracymethadol (9633)	I
3,4,5-Trimethoxyamphetamine (7390).	I	2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) (7521).	I	Norlevorphanol (9634)	I
4-Bromo-2,5-dimethoxyamphetamine (7391).	I	2-(2,5-Dimethoxy-4-(n-propylphenyl)ethanamine (2C-P) (7524).	I	Normethadone (9635)	I
4-Bromo-2,5-dimethoxyphenethylamine (7392).	I	2-(4-Isopropylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-4) (7532).	I	Trimeperidine (9646)	I
4-Methyl-2,5-dimethoxyamphetamine (7395).	I	MDPV (3,4-Methylenedioxypyrovalerone) (7535).	I	Phenmorphan (9647)	I
2,5-Dimethoxyamphetamine (7396).	I	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOME) (7536).	I	1-Methyl-4-phenyl-4-propionoxypiperidine (9661).	I
JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole (7398).	I	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOME) (7537).	I	Tilidine (9750)	I
2,5-Dimethoxy-4-ethylamphetamine (7399).	I	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOME) (7538).	I	Para-Fluorofentanyl (9812)	I
3,4-Methylenedioxymethamphetamine (7400).	I	Methyldone (3,4-Methylenediox-N-methylcathinone) (7540).	I	3-Methylfentanyl (9813)	I
5-Methoxy-3,4-methylenedioxymethamphetamine (7401).	I	Butylone (7541)	I	Thiofentanyl (9835)	I
N-Hydroxy-3,4-methylenedioxymethamphetamine (7402).	I	Pentylone (7542)	I	Amphetamine (1100)	II
3,4-Methylenediox-N-ethylamphetamine (7404).	I	alpha-pyrrolidinopentiophenone (alpha-PVP) (7545).	I	Methamphetamine (1105)	II
		alpha-pyrrolidinobutiophenone (alpha-PBP) (7546).	I	Lisdexamfetamine (1205)	II
		AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) (7694).	I	Phenmetrazine (1631)	II
		Acetylhydrocodeine (9051)	I	Methylphenidate (1724)	II
		Benzylmorphine (9052)	I	Amobarbital (2125)	II
		Codeine-N-oxide (9053)	I	Pentobarbital (2270)	II
		Desomorphine (9055)	I	Secobarbital (2315)	II
		Codeine methylbromide (9070)	I	Glutethimide (2550)	II
		Dihydromorphine (9145)	I	Nabilone (7379)	II
		Heroin (9200)	I	1-Phenylcyclohexylamine (7460)	II
				Phencyclidine (7471)	II
				1-Piperidinocyclohexanecarbonitrile (8603)	II
				Alphaprodine (9010)	II
				Cocaine (9041)	II
				Codeine (9050)	II
				Dihydrocodeine (9120)	II
				Oxycodone (9143)	II
				Hydromorphone (9150)	II
				Diphenoxylate (9170)	II
				Egonine (9180)	II
				Ethylmorphine (9190)	II
				Hydrocodone (9193)	II
				Levometorphan (9210)	II
				Levorphanol (9220)	II
				Isomethadone (9226)	II
				Meperidine (9230)	II
				Meperidine intermediate-A (9232)	II
				Meperidine intermediate-B (9233)	II
				Meperidine intermediate-C (9234)	II
				Metazocine (9240)	II
				Methadone (9250)	II
				Methadone intermediate (9254)	II

Controlled substance	Schedule
Dextropropoxyphene, bulk (non-dosage forms) (9273).	II
Morphine (9300)	II
Thebaine (9333)	II
Levo-alphacetylmethadol (9648) ..	II
Oxymorphone (9652)	II
Noroxyphorphone (9668)	II
Racemethorphan (9732)	II
Alfentanil (9737)	II
Remifentanil (9739)	II
Sufentanil (9740)	II
Carfentanil (9743)	II
Tapentadol (9780)	II
Fentanyl (9801)	II

The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.

Dated: August 19, 2014.

Joseph T. Rannazzisi,
Deputy Assistant Administrator.

[FR Doc. 2014-20201 Filed 8-25-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: PCAS-Nanosyn, LLC

ACTION: Notice of registration.

SUMMARY: PCAS-Nanosyn, LLC applied to be registered as a manufacturer of certain basic classes of narcotic and non-narcotic controlled substances. The DEA grants PCAS-Nanosyn, LLC registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the **Federal Register** on April 30, 2014, 79 FR 24452, PCAS-Nanosyn, LLC, 3331-B Industrial Drive, Santa Rosa, California 95403, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. No comments or objections have been received.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of PCAS-Nanosyn, LLC to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and

testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic and non-narcotic controlled substances listed:

Controlled substance	Schedule
Amphetamine (1100)	II
Methamphetamine (1105)	II
Methylphenidate (1724)	II
Phencyclidine (7471)	II
Codeine (9050)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Methadone (9250)	II
Morphine (9300)	II
Oripavine (9330)	II
Oxymorphone (9652)	II
Fentanyl (9801)	II

The company is a contract manufacturer. At the request of the company's customers, it manufactures derivatives of controlled substances only in bulk form.

Dated: August 19, 2014.

Joseph T. Rannazzisi,
Deputy Assistant Administrator.

[FR Doc. 2014-20196 Filed 8-25-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Patheon Pharmaceuticals, Inc.

ACTION: Notice of registration.

SUMMARY: Patheon Pharmaceuticals, Inc., applied to be registered as a manufacturer of a certain basic class of controlled substance. The DEA grants Patheon Pharmaceuticals, Inc., registration as a manufacturer of the controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated April 21, 2014, and published in the **Federal Register** on April 28, 2014, 79 FR 23373, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, applied to be registered as a manufacturer of a certain basic class of non-narcotic controlled substance. No

comments or objections have been received.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Patheon Pharmaceuticals, Inc., to manufacture the basic class of this controlled substance is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I.

The company plans to manufacture the listed controlled substance for distribution to its customers.

Dated: August 19, 2014.

Joseph T. Rannazzisi,
Deputy Assistant Administrator.

[FR Doc. 2014-20198 Filed 8-25-14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF LABOR

Office of the Secretary

Agency Information Collection Activities; Submission for OMB Review; Comment Request; Fire Protection in Shipyard Employment Standard

ACTION: Notice.

SUMMARY: The Department of Labor (DOL) is submitting the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, "Fire Protection in Shipyard Employment Standard," to the Office of Management and Budget (OMB) for review and approval for continued use, without change, in accordance with the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 et seq. Public comments on the ICR are invited.

DATES: The OMB will consider all written comments that agency receives on or before September 25, 2014.

ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely